Skepticism Greets Rare Disease Drug Maker CANbridge in Hong Kong IPO
Company’s shares tumble 27% in trading debut a week ago, but have stabilized since then on hopes for strong growth of China’s market for drugs to treat rare diseases Key…
RELATED ARTICLES
-
Why JL Mag came unstuck, but is getting back on track
6680.HK 300748.SHE
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
- HighTide Therapeutics places big IPO bet on “affluenza” drug
-
Everest reaches new heights on growing drug sales
1952.HK
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
- InSilico seeks IPO boost to get AI drugs over the line
Discover hidden China stock gems in our weekly newsletter